Cost analysis before and after initiation of biologic therapy in patients with severe asthma
Revista Alergia México · 2026
DOI: 10.29262/ram.v73i3.1596 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Revista Alergia México, 2026. Verfasst von Saraid Cerda Reyes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Head of the Allergy and Immunology Service, Medical Specialties Unit, Naucalpan, State of Mexico. saraid23@yahoo.com.mx. Hauptthemen laut MEDLINE: Asthma, Biological Therapy, Health Care Costs.
Abstract (Originalsprache)
OBJECTIVE: To estimate and compare healthcare resource utilization and direct medical costs in the year before and year after initiation of biologic therapy in patients with severe asthma. METHODS: A retrospective, observational study using a “before-and-after” evaluation design, conducted via a review of the institutional database of the Medical Specialties Unit in Naucalpan, State of Mexico. All healthcare resources utilized during the year prior to and the year following the initiation of biologic treatment were identified. To estimate the average cost per patient, direct medical costs associated with asthma treatment will be considered. RESULTS: The analysis included a total of 114 patients with severe asthma. In the descriptive comparison between the baseline year and the year after the initiation of biologic therapy, the total direct medical cost was $1,020.84 USD and $397.38 USD per patient, in average respectively. This was a difference of $623.46 USD per patient (61.1% reduction in mean costs). The number of recorded crisis/exacerbation events decreased during the year after biologic therapy initiation; however, events were identified from institutional records and were not independently adjudicated. CONCLUSIONS: Biologic therapy initiation was followed by lower recorded crisis events, healthcare resource utilization, and direct medical costs in this institutional cohort. Because of the retrospective before–after design and absence of an external control group, these findings should be interpreted as descriptive associations rather than causal effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Head of the Allergy and Immunology Service, Medical Specialties Unit, Naucalpan, State of Mexico. saraid23@yahoo.com.mx.
- MD. Medical Specialties Unit, Naucalpan, State of Mexico.
- MD, General Zone Hospital 58, Mexican Social Security Institute, Mexico City.
- MD, School of Medicine, University of Monterrey.
- MD, Children's Hospital of Mexico Federico Gómez, Mexico City.
- MD, Private practice.
ORCID-Profile: Saraid Cerda Reyes, Nidia Karen Castillon Benavides, Rosa Isela Campos Gutiérrez, Juan Gabriel Maldonado Hernández, Héctor Alberto Cuevas Mora, Joaquin Alberto Pimentel Hayashi
Zitieren
APA
Reyes, S. C., Benavides, N. K. C., Gutiérrez, R. I. C., Hernández, J. G. M., Mora, H. A. C., Verdugo, A. C., Rodríguez, E. M. N., & Hayashi, J. A. P. (2026). Cost analysis before and after initiation of biologic therapy in patients with severe asthma. Revista Alergia México. https://doi.org/10.29262/ram.v73i3.1596
Vancouver
Reyes SC, Benavides NKC, Gutiérrez RIC, Hernández JGM, Mora HAC, Verdugo AC, et al. Cost analysis before and after initiation of biologic therapy in patients with severe asthma. Revista Alergia México. 2026. doi:10.29262/ram.v73i3.1596
BibTeX
@article{Reyes2026,
author = {Reyes, Saraid Cerda and Benavides, Nidia Karen Castillon and Gutiérrez, Rosa Isela Campos and Hernández, Juan Gabriel Maldonado and Mora, Héctor Alberto Cuevas and Verdugo, Alejandro Cano and Rodríguez, Elsy Maureen Navarrete and Hayashi, Joaquin Alberto Pimentel},
title = {Cost analysis before and after initiation of biologic therapy in patients with severe asthma},
journal = {Revista Alergia México},
year = {2026},
doi = {10.29262/ram.v73i3.1596}
}
EUVIMED